6533b7d8fe1ef96bd126b618
RESEARCH PRODUCT
DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies
Gary S. FriedmanNervin LawendyAndrew John ThorpeDeborah A WoodworthM ChioreanChinyu SuD S ChapmanA. OrlandoKatsuyoshi MatsuokaChudy I. NduakaR Cohensubject
medicine.medical_specialtyTofacitinibOctave (poetry)business.industryOPEN LABEL TREATMENTGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisMaintenance therapyInternal medicinemedicineIn patientbusinessyear | journal | country | edition | language |
---|---|---|---|---|
2019-01-25 | Journal of Crohn's and Colitis |